HCPLive

Kynamro Approved for Genetic Condition Tied to Cholesterol

 
WEDNESDAY, Jan. 30 (HealthDay News) -- Kynamro (mipomersen sodium) has been approved by the U.S. Food and Drug Administration to treat homozygous familial hypercholesterolemia (HoFH), a rare inherited condition in which the body can't remove low-density lipoprotein (LDL) cholesterol from the blood, as an addition to lipid-lowering medications and diet.

Many people with HoFH have a heart attack and die before age 30, the FDA said in a news release. HoFH affects approximately one in every one million people in the United States. Kynamro is a once-weekly injection designed to lower creation of blood lipid particles that ultimately form LDL, the agency said.

The drug was clinically evaluated among 51 people with HoFH. Among Kynamro users, LDL levels fell an average of about 25 percent during the first 26 weeks, the FDA said. The drug will carry a "black box" label warning of possible liver abnormalities that could lead to progressive liver disease.

More common side effects noted during clinical testing included injection-site reactions, flu-like symptoms, nausea, headache, and elevated liver enzymes.

Kynamro is produced by Genzyme Corp., of Cambridge, Mass.
 

More Information


Copyright © 2013 HealthDay. All rights reserved.
 
 

Most Popular

Recommended Reading

Researchers investigating symptoms in people with self-reported aspartame sensitivity could find no substantive psychological or metabolic response to aspartame.
Cerebral blood flow recovery in the brain could demonstrate outcomes for patients following injury resulting in concussion, according to a study published in JAMA Neurology.
While less than 25% of centers in the United States offer kidney transplants to those infected with thehuman immunodeficiency virus (HIV), those patients are proving to have better outcomes than others following the surgery.
Black tea is popular and often promoted as healthy. But drinking too may be an under-recognized cause of kidney damage, a physician team warns in a case reported in the New England Journal of Medicine. The patient, who drank 16 glasses of iced tea daily, had kidney failure due to oxalate accumulation.
$vAR$